Cargando…

High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells

OBJECTIVE: It remains controversial whether tumour mutational burden (TMB) or neoantigens are prognostic markers in hepatocellular carcinoma (HCC). This study aimed to define the function of TMB or neoantigens in antitumour immunotherapy. DESIGN: Neoantigens of patients (n=56) were analysed by pVAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ting, Tan, Jizhou, Wu, Minhao, Fan, Wenzhe, Wei, Jialiang, Zhu, Bowen, Guo, Jian, Wang, Shutong, Zhou, Penghui, Zhang, Hui, Shi, Liangrong, Li, Jiaping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458084/ https://www.ncbi.nlm.nih.gov/pubmed/33262196 http://dx.doi.org/10.1136/gutjnl-2020-322196

Ejemplares similares

The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity
por: Zou, Fan, et al.
Publicado: (2021)

Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract
por: Kuo, Zong-Keng, et al.
Publicado: (2016)

Polyploidy spectrum: a new marker in HCC classification
por: Bou-Nader, Myriam, et al.
Publicado: (2020)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

CD14(+) CD15(−) HLA-DR(−) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure
por: Bernsmeier, Christine, et al.
Publicado: (2018)

Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro
por: Rossi, Marzia, et al.
Publicado: (2023)

TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication
por: Ho, Daniel W H, et al.
Publicado: (2017)

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
por: Pinyol, Roser, et al.
Publicado: (2019)

S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos
por: Wang, Xia, et al.
Publicado: (2023)

The human liver microenvironment shapes the homing and function of CD4(+) T-cell populations
por: Wiggins, Benjamin G, et al.
Publicado: (2022)

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study
por: De Toni, Enrico N, et al.
Publicado: (2020)

TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection
por: Heim, Kathrin, et al.
Publicado: (2021)

MicroRNA-206 promotes the recruitment of CD8(+) T cells by driving M1 polarisation of Kupffer cells
por: Liu, Ningning, et al.
Publicado: (2022)

Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis
por: Khamri, Wafa, et al.
Publicado: (2022)

Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8(+) T cells
por: Winkler, Frances, et al.
Publicado: (2023)

CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
por: van den Bulk, Jitske, et al.
Publicado: (2023)

CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism
por: Wilhelm, Annika, et al.
Publicado: (2016)

Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC
por: Wang, Dong, et al.
Publicado: (2019)

Impact of multiple liver resections prior to salvage liver transplantation on survival in patients with recurrent HCC
por: Hu, Zhenhua, et al.
Publicado: (2015)

Dysregulated activation of fetal liver programme in acute liver failure
por: Hyun, Jeongeun, et al.
Publicado: (2019)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

DNA mismatch repair and CD133-marked cancer stem cells in colorectal carcinoma
por: Cheah, Phaik-Leng, et al.
Publicado: (2018)

Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2019)

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
por: Zhang, Bo, et al.
Publicado: (2022)

Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review
por: Kenneally, Susan, et al.
Publicado: (2017)

Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies
por: Bankwitz, Dorothea, et al.
Publicado: (2021)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1(high)CD11b(+) cells elimination in hepatocellular carcinoma
por: Tan, Jizhou, et al.
Publicado: (2023)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance
por: Meng, Chao-Yang, et al.
Publicado: (2023)

Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36
por: Rey, Esther, et al.
Publicado: (2020)

Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling
por: Tao, Le, et al.
Publicado: (2019)

Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients
por: Zou, Zhengyu, et al.
Publicado: (2023)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy
por: Tang, Jia-Cheng, et al.
Publicado: (2019)

Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients
por: Jia, Kefeng, et al.
Publicado: (2023)

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer
por: Workel, Hagma H., et al.
Publicado: (2020)

Promoting antihepatocellular carcinoma activity against human HepG2 cells via pyridine substituted palladium complexes: in vitro evaluation and QSAR studies
por: MERAL, Öğünç, et al.
Publicado: (2023)

Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals
por: Fang, Fengqin, et al.
Publicado: (2016)

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
por: Schäkel, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_50u1j6ha6lp5c6njatuh47g5bl